BE Biosol Private Limited has entered into an agreement with the Gates Foundation. The goal is to develop and widen access to Ferric Carboxymaltose (FCM) injection. BE Biosol is a wholly owned subsidiary of Hyderabad-based Biological E. Limited. The collaboration aims to expand access to FCM injection in Africa and to help reduce the burden of anaemia there.

Ferric Carboxymaltose Injection IP 1000 mg/20 mL vial and carton, Inronx FCM by BE

Why the BE Biosol Gates Foundation Agreement Matters

Iron deficiency anaemia affects millions of people worldwide. It is especially common in low- and middle-income countries, where access to affordable treatment remains a challenge.

Under the agreement, the Gates Foundation will support BE Biosol in scale-up and clinical development of FCM injection for the target markets. BE Biosol will use its R&D capabilities and manufacturing infrastructure for the programme. The partnership also supports the clinical advancement and commercial readiness of the product at BE Biosol’s facilities.

Poultary

Manufacturing Strength Behind the Collaboration

BE Biosol’s manufacturing facility is in Shamirpet, Telangana, and was commissioned in 2018. It has been inspected and approved multiple times by leading regulators, including:

  • USFDA
  • Infarmed (Portugal)
  • UK MHRA
  • Brazil’s ANVISA

The collaboration combines the Gates Foundation’s commitment to global health with BE Biosol’s established manufacturing and regulatory capabilities.

Strategic Importance for BE Biosol

The agreement is strategic for BE Biosol as the US and European FCM markets approach a transition to generic competition. BE Biosol will use its manufacturing scale and proprietary API technology. It aims to build a differentiated, cost-competitive offering and a meaningful presence in these markets.

Narender Mantena on the Collaboration

Narender Mantena, Managing Director of BE Biosol Private Limited, said the collaboration reaffirms the company’s commitment to public health, which he called an important part of its legacy. He said it also reflects confidence in BE Biosol’s ability to develop and manufacture technologically demanding sterile formulations at competitive cost and scale.

He added that the collaboration reinforces the strategy of establishing BE Biosol as a globally competitive CDMO platform across complex biologics and pharmaceutical modalities.

About BE Biosol Private Limited

BE Biosol is the CDMO arm of Biological E. Limited, a Hyderabad-based pharmaceutical and biologics company founded in 1953. It builds on the group’s expertise and track record in vaccines. BE Biosol is developing a differentiated and globally competitive CDMO platform that serves biopharmaceutical partners from development through commercialisation.

Its focus areas include:

  • Vaccines
  • Monoclonal antibodies (mAbs)
  • Antibody-drug conjugates (ADCs)
  • mRNA therapeutics
  • Complex injectable products
Bharati Cement

LEAVE A REPLY

Please enter your comment!
Please enter your name here